Emerald Mutual Fund Advisers Trust cut its holdings in shares of Catalent Inc (NYSE:CTLT) by 14.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 371,351 shares of the company’s stock after selling 64,820 shares during the period. Emerald Mutual Fund Advisers Trust owned about 0.26% of Catalent worth $16,915,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the stock. Janus Henderson Group PLC lifted its position in shares of Catalent by 4.3% in the 2nd quarter. Janus Henderson Group PLC now owns 6,400,737 shares of the company’s stock worth $268,127,000 after purchasing an additional 266,183 shares during the period. FMR LLC lifted its position in shares of Catalent by 1.5% in the 2nd quarter. FMR LLC now owns 3,781,793 shares of the company’s stock worth $158,420,000 after purchasing an additional 54,678 shares during the period. American Century Companies Inc. lifted its position in shares of Catalent by 6.4% in the 2nd quarter. American Century Companies Inc. now owns 3,052,515 shares of the company’s stock worth $127,870,000 after purchasing an additional 183,880 shares during the period. Earnest Partners LLC lifted its position in shares of Catalent by 0.3% in the 2nd quarter. Earnest Partners LLC now owns 2,548,094 shares of the company’s stock worth $106,740,000 after purchasing an additional 7,628 shares during the period. Finally, Macquarie Group Ltd. lifted its position in shares of Catalent by 25.2% in the 2nd quarter. Macquarie Group Ltd. now owns 2,349,059 shares of the company’s stock worth $98,402,000 after purchasing an additional 472,228 shares during the period. Institutional investors and hedge funds own 91.80% of the company’s stock.
CTLT has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research report on Monday, September 3rd. UBS Group started coverage on shares of Catalent in a research report on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Wednesday, August 29th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $49.33.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, August 28th. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.06. The company had revenue of $685.30 million during the quarter, compared to analyst estimates of $690.69 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. Catalent’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.65 EPS. Analysts forecast that Catalent Inc will post 1.72 EPS for the current fiscal year.
In other Catalent news, SVP Lance Miyamoto sold 6,525 shares of the business’s stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $42.50, for a total transaction of $277,312.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John R. Chiminski sold 130,545 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $45.32, for a total transaction of $5,916,299.40. The disclosure for this sale can be found here. Insiders sold a total of 184,335 shares of company stock valued at $8,161,727 in the last quarter. 1.40% of the stock is currently owned by company insiders.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: What is a stock buyback?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.